Highest-materiality recent filing
BioCorRx director Kate Beebe DeVarney resigns from board effective Aug 31, 2026
Kate Beebe DeVarney, Ph.D. resigned from BioCorRx board effective August 31, 2026.
BioCorRx acquires additional 12.15% of subsidiary via stock-for-stock exchange with insiders
Entered stock exchange agreement with CEO, President, and board member to transfer 1,215 subsidiary shares for 2,263,371 parent shares.
BioCorRx enters $350K securities purchase agreement for 1M shares and warrants
Aggregate purchase price of $350,000 for 1,000,000 shares of common stock and warrants to purchase up to 1,000,000 shares.
BioCorRx acquires FDA-approved opioid withdrawal drug Lucemyra from USWM LLC
Upfront purchase price of $400,000 paid via seller retention of 50% of net sales and net distributable profits until capped.
BioCorRx dismisses Marcum LLP auditor, appoints M&K CPAS; prior reports flagged going concern
Board dismissed Marcum LLP and engaged M&K CPAS as independent auditor for fiscal 2024.
Two directors resign from BioCorRx board; no stated disagreements
Brady Granier resigned from board effective March 31, 2024.
BioCorRx President Brady Granier resigns; Louis Lucido appointed as President
Brady Granier resigned as President of BioCorRx and CEO of BioCorRx Pharmaceuticals, effective Jan 31, 2024; remains on board.
BioCorRx raises $200K via note, warrant & inducement shares; note matures Sep 2024
Issued $220K principal note (8% OID) for $200K cash; unsecured, matures Sep 8, 2024.
BioCorRx raises $200K from LGH via $220K note, warrant, and 24K inducement shares
Sold $220K promissory note (8% one-time interest) for $200K purchase price; $20K OID.
BioCorRx President Brady Granier takes paid leave; CEO Lourdes Felix assumes duties
President Brady Granier granted paid administrative leave from Oct 30, 2023 to Jan 30, 2024; remains on board.
BioCorRx raises $300K via common stock and warrant sale to accredited investor
Sold 174,409 shares of common stock at $1.72/share for total proceeds of $300,000.
BioCorRx raises $600k from directors via stock and warrants; converts $314k note to equity
Directors Galligan and Lucido each invest $300k at $1.75/share, receive warrants for equal shares at $4.00.
BioCorRx appoints Harsha Murthy to board of directors
Harsha Murthy appointed as director effective January 20, 2023.
BioCorRx changes independent auditor to Marcum LLP after Friedman merger
Friedman LLP combined with Marcum LLP effective Sept 1, 2022; BOD engaged Marcum LLP on Oct 21, 2022 for FY2022 audit.
BioCorRx ordered to pay $235,886 in legal fees to Pellecome; Company files appeal
Court entered judgment against BioCorRx for $235,886 in costs and attorneys' fees, plus 10% annual interest from Oct 6, 2021.
BioCorRx raises $250K in private placement of stock and warrants
Issued 110,619 common shares at $2.26/share to accredited investor on May 6, 2022.
BioCorRx adopts 2022 Omnibus Plan authorizing 695,000 shares for equity incentives
Board approved 2022 Omnibus Securities and Incentive Plan on April 22, 2022; replaces 2018 plan.
BioCorRx raises $1M via private placement of 229,886 shares at $4.35/share to two directors
Gross proceeds of $1M from sale of 229,886 shares at $4.35 per share to Lucido and Galligan trusts.
BioCorRx awarded $3.5M NIDA grant for first-in-human trial of BICX104 implant
Award of ~$3.5M from NIDA for second phase (UH3) of grant; total NIDA funding now ~$5.7M.
On August 31, 2026, Kate Beebe DeVarney, Ph.D. submitted her resignation from her position as a member of the board of directors (the “Board”) of BioCorRx Inc.(the “Company”), effective August 31, 2026 (the “DeVarney Resignation”).
Additionally, on March 29, 2024, Harsha Murthy submitted his letter of resignation from his position as a member of the Board of the Company, effective April 2, 2024 (the “ Murthy Resignation ”).
On March 29, 2024, Brady Granier submitted his letter of resignation from his position as a member of the board of directors (the “ Board ”) of BioCorRx Inc. (the “ Company ”), effective March 31, 2024 (the “ Granier Resignation ”).
On January 5, 2024, in light of the Granier Resignation, the Board appointed Louis Lucido as Interim President of the Company, effective immediately through January 31, 2024, and transitioning to President on February 1, 2024
On December 29, 2023, Brady Granier submitted his letter of resignation as President of BioCorRx Inc. (the “ Company ”) and Chief Executive Officer of BioCorRx Pharmaceuticals, a subsidiary of the Company, effective January 31, 2024
On October 30, 2023, the board of directors (the “Board”) of BioCorRx Inc. (the “Company”) approved Brady Granier’s request for a paid administrative leave of absence from his position as the President of the Company for the period between October 30, 2023 and January 30, 2024.
On January 20, 2023, BioCorRx, Inc. (the “Company”) appointed Harsha Murthy as a member of the Board of Directors (the “Board”) of the Company (the “Murthy Appointment”).
Max materiality 0.75 · Median 0.50 · Most common event other_material